Theeoretical models for drug delivery to solid tumors

Critical Reviews in Biomedical Engineering

Volumn 25, Issue 6, 1997, Pages 503-571

  El Kareh, A W ^a   Secomb, T W ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Blood vessel; Chemotherapy; Compartmental models; Convection; Diffusion; Interstitium; Mathematical model

Indexed keywords

ALBUMIN; AMSACRINE; ANTINEOPLASTIC AGENT; ASULACRINE ISETHIONATE; BLEOMYCIN A2; BOVINE SERUM ALBUMIN; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; DNA; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 2; IODINE 125; IODINE 131; LIPOSOME; MONOCLONAL ANTIBODY; OXYGEN; PACLITAXEL; POLYMER; VINBLASTINE; VINCRISTINE;

AEROSOL; AREA UNDER THE CURVE; BLOOD VESSEL; CELL KILLING; CELL KINETICS; CELL TRANSPORT; DIFFUSION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TRANSPORT; DRUG UPTAKE; ENCAPSULATION; HUMAN; HYPERTHERMIA; IMPLANT; INFUSION; INHALATIONAL DRUG ADMINISTRATION; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATHECAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MATHEMATICAL MODEL; MODEL; NONHUMAN; PERMEABILITY; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; THERMODYNAMICS; TISSUE PRESSURE; TOPICAL DRUG ADMINISTRATION; TUMOR BLOOD FLOW; ANIMAL; BIOLOGICAL MODEL; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS;

BLOOD VESSELS; CONTROLLED DRUG DELIVERY; ENCAPSULATION; ENZYMES; HYPERTHERMIA THERAPY; MATHEMATICAL MODELS; ONCOLOGY; PHARMACOKINETICS;

INTRAARTERIAL DRUG DELIVERY; INTRAPERITONEAL DRUG DELIVERY; INTRATHECAL DRUG DELIVERY; INTRATUMORAL DRUG DELIVERY; INTRAVENOUS DRUG DELIVERY; LIPOSOME; MAGNETIC TARGETING;

CHEMOTHERAPY;

EID: 0031282884     PISSN: 0278940X     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevBiomedEng.v25.i6.20     Document Type: Review

References (250)

1. Strasser, J. F., Fung, L. K., Grossman, S. A., and Saltzman, W. M., Distribution of 1,3- bis(2-chloroethyl)-1-nitrosourea and tracers in the rabbit brain after interstitial delivery by biodegradable polymer implants, J. Pharmacol. Exp. Ther., 275, 1647-1655, 1995.
2. West, G. W., Weichselbaum R., and Little J. B., Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy, Cancer Res., 40(10), 3665-3668, 1980.
3. Sands, H., Jones, L., Shah, S. A., Palme, D., Vessella, R. L., and Gallagher, B. M., Correlation of vascular permeability and blood flow with monoclonal antibody uptake by human Clouser and renal cell xenografts, Cancer Res., 48, 188-193, 1988.
4. Hemingway, D. M., Angerson, W. J., Anderson, J. H., Goldberg, J. A., McArdle, C. S., and Cooke, T. G., Monitoring blood flow to colorectal liver metastases using laser Doppler flowmetry: the effect of angiotensin II, Br. J. Cancer, 66(5), 958-960, 1992.
5. Lamer, S., Sigal, R., Lassau, N., Bosq, J., Frouin, F., Di Paola, M., Mamelle, G., Leclere, J., Bittoun, J., and Di Paola, R., Radiologic assessment of intranodal vascularity in head and neck squamous cell carcinoma. Correlation with histologic vascular density, Invest. Radial., 31(11), 673-679, 1996.
6. Abe, I., Suzuki, M., Hori, K., Saito, S., and Sato, H., Some aspects of size-dependent differential drug response in primary and metastatic tumors, Cancer Metastasis Rev., 4(1), 27-39, 1985.
7. Jain, R. K., Delivery of novel therapeutic agents in tumors: physiological barriers and strategies, J. Natl. Cancer Inst., 81, 570-576, 1989.
8. Jain, R. K., Barriers to drug delivery in solid tumors, Sci. Am., 271(1), 58-65, 1994.
9. Jain, R. K., Whitaker Lecture: delivery of molecules, particles, and cells to solid tumors, Ann. Biomed. Eng., 24(4), 457-473, 1995.
10. Jain, R. K., Delivery of molecular medicine to solid tumors, Science, 271(5252), 1079- 1080, 1996.
11. Jain, R. K., Delivery of molecular and cellular medicine to solid tumors, Microcirculation, 4(1), 1-23, 1997.
12. Masson, E. and Zamboni, W. C., Pharmacokinetic optimization of cancer chemotherapy. Effect on outcomes, Clin. Pharmacokinet., 32(4), 324-343, 1997.
13. Goren, D., Horowitz, A. T., Zalipsky, S., Woodle, M. C., Yarden, Y., and Gabizon, A., Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies, Br. J. Cancer, 74(11), 1749-1756, 1996.
14. Ahmad, I. and Alien, T. M., Antibody-mediated specific binding and cytotoxicity of liposome-entrapped doxorubicin to lung cancer cells in vitro, Cancer Res., 52, 4817-4820, 1992.
15. Vaughan, A. T. M., Anderson, P., Dykes, P. W., Chapman, C. E., and Bradwell, A. R., Limitations to the killing of tumors using radiolabeled antibodies, Br. J. Radiol, 60, 567-578, 1987.
16. Endlich, B., Reinhold, H. S., Gross, J. F., and Intaglietta, M., Tissue perfusion inhomogeneity during early tumor growth in rats, J. Natl. Cancer Inst., 62(2), 387-395, 1979.
17. Baxter, L. T. and Jain, R. K., Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection, Microvasc. Res., 31, 77-104, 1989.
18. Baxter, L. T. and Jain, R. K., Transport of fluid and macromolecules in tumors. II. Role of heterogeneous perfusion and lymphatics, Microvasc. Res., 40, 246-263, 1990.
19. Baxter, L. T. and Jain, R. K., Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism, Microvasc. Res., 41, 5-23, 1991.
20. Baxter, L. T. and Jain, R. K., Transport of fluid and macromolecules in tumors, jy. A- microscopic model of the perivascular distribution, Microvasc. Res., 41, 252-272, 1990.
21. Ames, M. M., Powis, G., and Kovach, J. S., Eds., Pharmacokinetics of Anticancer Agents in Humans, Elsevier, Amsterdam, 1983.
22. Strand, S. E., Zanzonico, P., and Johnson, T. K., Pharmacokinetic modeling, Med. Phys., 20, 515-527, 1993.
23. Gamelin, E. C., Danquechin-Dorval, E. M., Dumesnil, Y. F., Maillait, P. J., Goudier, M. J., Burtin, P. C., Delva, R. G., Lortholary, A. H., Gesta, P. H., and Larra, F. G., Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU, Cancer, 77(3), 441-451, 1996.
24. Balis, F. M., Holcenberg, J. S., and Bleyer, W. A., Clinical pharmacokinetics of commonly used anticancer drugs, Clin. Pharmacokinet., 8(3), 202-232, 1983.
25. Piscitelli, S. C., Rodvold, K. A., Rushing, D. A., and Tewksbury, D. A., Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer, Clin. Pharmacol. Ther., 53(5), 555-561, 1993.
26. Sadee, W. and Wong, C. G., Pharmacokinetics of 5-fluorouracil: interrelationship with biochemical kinetics in monitoring therapy, Clin. Pharmacokinet., 2(6), 437-450, 1977.
27. Muller, M., Mader, R. M., Steiner, B., Steger, G. G., Jansen, B., Gnant, M., Helbich, T., Jakesz, R, Eichler, H. G., and Blochl-Daum, B., 5-fluorouracil kinetics in the interstitial tumor space: clinical response in breast cancer patients, Cancer Res., 57(13), 2598-2601, 1997.
28. Goitein, M. and Schultheiss, T. E., Strategies for treating possible tumor extension: some theoretical considerations, Int. J. Radial. Oncol. Biol. Phys., 11(8), 1519-1528, 1985.
29. Sgouros, G., Radioimmunotherapy of micrometastases; sidestepping the solid-tumor hurdle, J. Nucl. Med., 36(10), 1910-1912, 1995.
30. Baguley, B. C. and Finlay, G. J., Pharmacokinetic/cytokinetic principles in the chemotherapy of solid tumors, Clin. Exp. Pharmacol Physiol, 22(11), 825-828, 1995.
31. Nguyen-Ngoc, T., Vrignaud, P., and Robert, J., Cellular pharmacokinetics of doxorubicin in cultured mouse sarcoma cells originating from autochthonous tumors, Oncology, 41(1), 55-60, 1984.
32. Juliano, R. L. and Stamp, D., Pharmacokinetics of liposome-encapsulated anti-tumor drugs, Biochem. Pharmacol., 27, 21-27, 1978.
33. Swan, G. W., General applications of optimal control theory in cancer chemotherapy, IMA J. Math. Appl. Med. Biol., 5(4), 303-316, 1988.
34. Covell, D. G., Barbet, J., Holton, O. D., Black, C. D., Parker, R. J., and Weinstein, J. N., Pharmacokinetics of monoclonal immunoglobulin GJ, F(ab′)2, and Fab′ in mice, Cancer Res., 46(8), 3969-3978, 1986.
35. Sung, C., Blaney, S. M., Cole, D. E., Balis, F. M., and Dedrick, R. L., A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid, Cancer Res., 54(19), 5118-5122, 1994.
36. Beatty, B. G., Beatty, J. D., Williams, L. E., Paxton, R. J., Shively, J. E., and O'Connor-Tressel, M., Effect of specific antibody pretreatment on liver uptake of 111In-labeled anticarcinoembryonic antigen monoclonal antibody in nude mice bearing human colon cancer xenografts, Cancer Res., 49(6), 1587-1594, 1989.
37. Eger, R. R., Covell, D. G., Carrasquillo, J. A., Abrams, P. G., Foon, K. A., Reynolds, J. C., Schroff, R. W., Morgan, A. C., Larson, S. M., and Weinstein, J. N., Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans, Cancer Res., 47(12), 3328-3336, 1987.
38. Litterst, C. L. and Magin, R., Alterations in plasma pharmacokinetics of cisplatin in tumorbearing rats, Cancer Chemother. Pharmacol, 22(1), 1-4, 1988.
39. Chen, H.-S. G. and Gross, J. F., Estimation of tissue-to-plasma partition coefficients used in physiological pharmacokinetic models, J. Pharmacokinet. Biopharm., 7, 117-125, 1979.
40. Terasaki, T., Sugiyama, Y., Iga, T., Sawada, Y., and Hanano, M., Theoretical consideration of drug distribution kinetics in a noneliminating organ: comparison between a "homogeneous (well-stirred)" model and "nonhomogeneous (tube)" model, J. Pharmacokinet. Biopharm., 13(3), 265-287, 1985.
41. Farris, F. F., Dedrick, R. L., and King, F. G., Cisplatin pharmacokinetics: applications of a physiological model, Toxicol. Lett., 43, 117-137, 1988.
42. Presant, C. A., Wolf, W., Albright, M. J., Servis, K, L., Ring, R., III, Atkinson, D., Ong, R. L., Wiseman, C., King, M., Blayney, D., et al., Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics, J. Clin. Oncol., 8(11), 1868-1873, 1990.
43. Wolf, W., Presant, C. A., Servis, K. L., El-Tahtawy, A., Albright, M. J., Barker, P. B., Ring, R., III, Atkinson, D., Ong, R., King, M., et al., Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits, Proc. Natl. Acad. Sci. U.S.A., 87(1), 492-496, 1990.
44. Guerquin-Kern, J. L., Leteurtre, F., Croisy, A., and Lhoste, J. M., pH dependence of 5-fluorouracil uptake observed by in vivo 31P and 19F nuclear magnetic resonance speçtroscopy. Cancer Res., 51(20), 5770-5773, 1991.
45. Kameyama, M., Fukuda, I., Imaoka, S., Furukawa, H., Ishikawa, O., Kabuto, T., Sasaki, Y., Hiratsuka, M., Shibaga, T., Koyama, H., et al., Stagnation of liver blood and effectiveness of intra-arterial chemotherapy in metastatic colorectal cancer, (in Japanese), Gan to Kagaku Ryoho, Japanese Journal of Cancer and Chemotherapy, 16, 2894-2896, 1989.
46. Baxter, L. T. and Jain, R. K., Pharmacokinetic analysis of the microscopic distribution of enzyme-conjugated antibodies and prodrugs: comparison with experimental data, Br. J. Cancer, 73(4), 447-456, 1996.
47. Baxter, L. T., Yuan, F., and Jain, R. K., Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data, Cancer Res., 52(20), 5838-5844, 1992.
48. Yuan, F., Baxter, L. T., and Jain, R. K., Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies, Cancer Res., 51(12), 3119-3130, 1991.
49. Baxter, L. T., Zhu, H., Mackensen, D. G., Butler, W. F., and Jain, R. K., Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based Pharmacokinetic model, Cancer Res., 55(20), 4611-4622, 1995.
50. Sung, C., Shockley, T. R., Morrison, P. F., Dvorak, H. F., Yarmush, M. L., and Dedrick, R. L., Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors, Cancer Res., 52(2), 377-384, 1992.
51. Thomas, G. D., Chappell, M. J., Dykes, P. W., Rameden, D. B., Godfrey, K. R., Ellis, J. R., and Bradwell, A. R., Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model, Cancer Res., 49(12), 3290-3296, 1989.
52. Middleman, S., Transport Phenomena in the Cardiovascular System, Wiley-Interscienee, New York, 1972.
53. Swabb, E. A., Wei, J., and Gullino, P. M., Diffusion and convection in normal and neoplastic tissues, Cancer Res., 34(10), 2814-2822, 1974.
54. Young, R. C., Mechanisms to improve chemotherapy effectiveness, Cancer, 65(3 Suppl), 815-822, 1990.
55. Shockley, T. R., Lin, K., Nagy, J. A., Tompkins, R. G., Yarmush, M. L., and Dvorak, H. F., Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts, Cancer Res., 52(2), 367-376, 1992.
56. Sung, C., Dedrick, R. L., Hall, W. A., Johnson, P. A., and Youle R. J., The spatial distribution of immunotoxins in solid tumors: assessment by quantitative autoradiography, Cancer Res., 53(9), 2092-2099, 1993.
57. Williams, L. E., Duda, R. B., Proffitt, R. T., Beatty, B. G., Beatty; J. D., Wong, J. Y., Shively, J. E., and Paxton, R. J., Tumor uptake as a function of tumor mass: a mathematic model, J. Nucl. Med., 29(1), 103-109, 1988.
58. Williams, L. E., Bares, R. B., Fass, J., Hauptmann, S., Schumpelick, V., and Buell, U., Uptake of radiolabeled anti-CEA antibodies in human colorectal primary tumors as a function of tumor mass, Eur. J. Nucl. Med., 20(4), 345-347, 1993.
59. Pedley, R. B., Boden, J., Keep, P. A., Harwood, P. J., Green, A. J., and Rogers, G. T., Relationship between tumor size and uptake of radiolabeled anti-CEA in a colon tumor xenograft,Eur. J. Nucl. Med., 13(4), 197-202, 1987.
60. Cheung, N. K., Neely, J. E., Landmeier, B., Nelson, D., and Miraldi F., Targeting of ganglioside GD2 monoclonal antibody to neuroblastoma, J. Nucl. Med., 28(10), 1577-1583, 1987.
61. Weinstein, J. N. and van Osdol, W., Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier", Cancer Res., 52(9 Suppl), 2747s-2751s, 1992.
62. Blumenthal, R. D., Fand, I., Sharkey, R. M., Boerman, O. C., Kashi, R., and Goldenberg, D. M., The effect of antibody protein dose on the uniformity of tumor distribution of radioantibodies: an autoradiographic study, Cancer Immunol. Immunother., 33(6), 351-358, 1991.
63. Ahmad, I., Longenecker, M., Samuel, J., and Allen, T. M., Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice, Cancer Res., 53(7), 1484-1488, 1993.
64. Froment, G. F. and Bischoff, K. B., Chemical Reactor Analysis and Design, John Wiley, New York, 1979, 179.
65. Fujimori, K., Covell, D. G., Fletcher, J. E., and Weinstein, J, N., Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab′)2, and Fab in tumors, Cancer Res., 49(20), 5656-5663, 1989.
66. Juweid, M., Strauss, H. W., Yaoita, H., Rubin, R. H., and Fischman, A. J., Micropbarmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier, Cancer Res., 52, 5144-5153, 1992.
67. Schlom, J., Eggensperger, D., Colcher, D., Molinolo, A., Houchens, D., Miller, L. S., Hinkle, G., and Siler, K., Therapeutic advantage of high-affinity anticarcinoma radioimmunoconjugates, Cancer Res., 52(5), 1067-1072, 1992.
68. Gaze, M. N., Mairs, R. J., Boyack, S. M., Wheldon, T. E., and Barrett, A., 131Imetaiodobenzylguanidine therapy in neuroblastoma spheroids of different sizes, Br. J. Cancer, 66(6), 1048-1052, 1992.
69. Humm, J. L. and Chin, L. M., A model of cell inactivation by alpha-particle internal emitters, Radiat. Res., 134(2), 143-150, 1993.
70. Langmuir, V. K., Mendonca, H. L., and Woo, D. V., Comparisons between two monoclonal antibodies that bind to the same antigen but have differing affinities: uptake kinetics and 1251-antibody therapy efficacy in multicell spheroids. Cancer Res., 52(17), 4728-4734, 1992.
71. Buchsbaum, D. J., Wahl, R. L., Glenn, S. D., Normolle, D. P., and Karninski, M, S., Improved delivery of radiolabelled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody, Cancer Res., 52, 637-642, 1992.
72. Futscher, B. W. and Dalton, W. S., P-glycoprotein mediated multidrug resistance, in Drug Resistance in Oncology, Teicher, B. A., Ed., Dekker, New York, 1993, 461-478.
73. Ramu, A., Pollard, H. B., and Rosario, L. M., Doxorubicin resistance in P388 leukemia- evidence for reduced drug influx, Mr. J. Cancer, 44(3), 539-547, 1989.
74. Frezard, F. and Garnier-Suillerot, A., Comparison of the-membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells, Eur. J. Biochem., 196(2), 483-491, 1991.
75. Furu, K., Kilvik, K., Gautvik, K. M., and Haug, E., The mechanism of [3H]dexamethasone uptake into prolactin producing rat pituitary cells (GH3 cells) in culture, J. Steroid Biochem., 28(6), 587-591, 1987.
76. Rougier, P., Ducreux, M., Elias, D., and Lasser, P., Hepatic metastases of colorectal cancers; intra-arterial chemotherapy. Value and indications (In French), (Metastases hepatiques des cancers colorectaux: chimiotherapies intra-arterielles. Interet et indications), Presse Med., 25(35), 1683-1688, 1996.
77. Murakami, M., Yoden, E., Kono, K., Okamoto, Y., Maetani, Y., Sai, H., Kobayashi, K., Sasaki, R., Kazawa, N., Sano, A., and Kuroda Y., Experience in treatment of patients with locally advanced or recurrent breast cancer: intraarterial infusion chemotherapy combined with radiotherapy (In Japanese), Nippon Igaku Hoshasen Gakkai Zasshi, Nippon Acta Radiologica, 57(4), 189-194, 1997.
78. Zyrianov, B. N., Makarkin, N. A., Tikhonov, V. I., and Tuzikov, S. A., The combined treatment of locally disseminated stomach cancer with intra-arterial regional chemotherapy (In Russian), (Kombinirovannoe lechenie mestnorasprostranennogo rake zheludka s vnutriarterial'noi regionarnoi khimioterapii), Khirurgiia, 6, 13-16, 1996.
79. Simonetti, R. G., Liberati, A., Angiolini, C., and Pagliaro, L., Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials, Ann. Oncol, 8(2), 117-136, 1997.
80. Hassenbusch, S. J., Anderson, J. H., and Colvin, O. M., Predicted and actual BCNU concentrations in normal rabbit brain during intraarterial and intravenous infusions, J. Neurooncol., 30(1), 7-18, 1996.
81. Dedrick, R. L., Arterial drug infusion: pharmacokinetic problems and pitfalls, J. Natl. Cancer Inst., 80, 84-89, 1988.
82. Saris, S. C., Blasberg, R. G., Carson, R. E., deVroom, H. L., Lutz, R., Dedrick, R. L., Pettigrew, K., Chang, R., Doppman, J., Wright, D. C., et al., Intravascular streaming during carotid artery infusions. Demonstration in humans and reduction using diastole-phased pulsatile administration, J. Neurosurg., 74(5), 763-772, 1991.
83. Eckmann, W. W., Patlak, C. S., and Fenstermacher, J. D., A critical evaluation of the principles governing the advantages of intra-arterial infusions, J. Pharmacokinet. Biopharm., 2(3), 257-285, 1974.
84. Chen, H. S. and Gross, J. F., Intra-aiterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses, Cancer Treat. Rep., 64(1), 31-40, 1980.
85. Taton, G., Ghanem, G., Pandin, P., Goldzarian, J., Thaysse, C., Bertin, L., Ick, B., Medhi, A., Salari, A., Vanherweghem, J. L., and Lambilliotte, J. P., First results of a clinical pilot study on intraarterial chemotherapy with haemofiltration of locally advanced gastrointestinal cancers, Acta Chir. Belg., 96(5), 206-210, 1996.
86. Baxter, L. T., Zhu, H., Mackensen, D. G., and Jain R. K., Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice, Cancer Res., 54(6), 1517-1528, 1994.
87. Sung, C., Youle, R. J., and Dedrick R. L., Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding, Cancer Res., 50(22), 7382-7392, 1990.
88. Levick, J. R., Fluid exchange across endothelium, Int. J. Microcirc., 17, 241-247, 1997.
89. Levick, J. R., An Introduction to Cardiovascular Physiology, Butterworths, London, 1990.
90. Baish, J. W., Netti, P., and Jain, R. K., Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors, Microvasc. Res., 53, 128-141, 1997.
91. Zlotecki, R. A., Boucher, Y., Lee, I., Baxter, L. T., and Jain, R. K., Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure, Cancer Res., 53(11), 2466-2468, 1993.
92. Boucher, Y. and Jain, R. K., Microvascular pressure is the principal driving force for interstitial hypertension ia solid tumors: implications for vascular collapse, Cancer Res., 52(18), 5110-5114, 1992.
93. Stone, H. B., Minchinton, A. I., Lemmon, M., Menke, D., and Brown, J. M., Pharmacological modification of tumor blood flow: lack of correlation between alteration of mean arterial blood pressure and changes in tumor perfusion, Int. J. Radiat. Oncol Biol. Phys., 22(1), 79-86, 1992.
94. Sato, H., Sugiyama, K., Hoshi, M., Urushiyama, M., and Ishizuka, K., Angiotensin II (All) induced hypertension chemotherapy (IHC) for unresectable gastric cancer: with reference to resection after down staging, World J. Surg., 19(6), 836-842, 1995.
95. Minchinton, A. I. and Fryer, K. H., Fluctuations in the oxygenation of experimental tumours, Adv. Exp. Med. Biol., 388, 353-356, 1996.
96. Kimura, H., Braun, R. D., Ong, E. T., Hsu, R., Secomb, T. W., Papahadjopoulos, D., Hong, K., and Dewhirst M. W., Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma, Cancer Res., 56, 5522-5528, 1996.
97. Flessner, M. F., Dedrick, R. L., and Schultz, J. S., A distributed model of peritoneal-plasma transport: theoretical considerations, Am. J. Physiol, 246, R597-R607, 1984.
98. Deng, C., Huang, R., and Lian, L., Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer (In Chinese), Chung-Hua Fu Chan Ko Tsa Chih, Chinese Journal of Obstetrics and Gynecology, 31(3), 159-162, 1996.
99. Ward, B. G. and Wallace, K., Localisation of the monoclonal antibody HMFG2 after intravenous and intraperitoneal injection into nude mice bearing subcutaneous and intraperitoneal human ovarian cancer xenografts, Cancer Res., 47(17), 4714-4718, 1987.
100. Ward, B. G., Mather, S. J., Hawkins, L. R., Crowther, M. E., Shepherd, J. H., Granowska, M., Britton, K. E., and Slevin, M. L., Localization of radioiodine conjugated to the monoclonal antibody HMFG2 in human ovarian carcinoma: assessment of intravenous and intraperitoneal routes of administration, Cancer Res., 47(17), 4719-4723, 1987.
101. Markman, M., Francis, P., Rowinsky, E., Hakes, T., Reichman, B., Jones, W., Lewis, J. L., Jr., Rubin, S., Curtin, J., Barakat, R., et al., Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancer, Ann. Oncol, 5(Suppl 6), S55-S58, 1994.
102. Flessner, M. F., Dedrick, R. L., and Reynolds, J. C., Bidirectional peritoneal transport of immunoglobulin in rats: compartmental kinetics, Am. J. Physiol, 262(2 Pt 2), F275-F287,1992.
103. Kerr, D. J., Young, A. M., Neoptolemos, J. P., Sherman, M., Van-Geene, P., Stanley, A., Ferry, D., Dobbie, J. W., Vincke, B., Gilbert, J., El Eini, D., Dombros, N., and Fountzilas, G., Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution, Br. J. Cancer, 74(12), 2032-2035, 1996.
104. Lindner, P., Heath, D. D., Shalinsky, D. R., Howell, S. B., Naredi, P., and Hafstrom, L., Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide, Surg. Oncol, 2(2), 105-112, 1993.
105. Sharma, A., Sharma, U. S., and Straubinger, R. M., Paclitaxel-liposomes for intracavitary therapy of intraperitoneal P388 leukemia, Cancer Lett, 107(2), 265-272, 1996.
106. Speyer, J. L. and Myers, C. E., The use of peritoneal dialysis for delivery of chemotherapy to intraperitoneal malignancies, Recent Results Cancer Res., 74, 264-269, 1980.
107. Balthasar, J. and Fung, H. L., Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug, J. Pharmacol Exp. Ther., 268(2), 734-739, 1994.
108. Dedrick, R. L. and Flessner, M. F., Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure, J, Natl Cancer Inst., 89(7), 480-487, 1997.
109. Flessner, M. F. and Schwab, A., Pressure threshold for fluid loss from the peritoneal cavity, Am. J. Physiol, 270(2 Pt 2), F377-F390, 1996.
110. Kondo, A., Maeta, M., Oka, A., Tsujitani, S., Ikeguchi, M., and Kaibara, N., Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice, Br. J. Cancer, 73(10), 1166-1170, 1996.
111. Jacquet, P., Stuart, O. A., Chang, D., and Sugarbaker, P. H., Effects of intra-abdominal pressure on pharmacokinetics and tissue distribution of doxorubicin after intraperitoneal administration, Anticancer Drugs, 7(5), 596-603, 1996.
112. Seames, E. L., Moncrief, J. W., and Poppvich, R. P., A distributed model of fluid and mass transfer in peritoneal dialysis, Am. J. Physiol, 258, R958-R972, 1990.
113. Flessner, M. F., Dedrick, R. L., and Schultz, J. S., Exchange of macromolecules between peritoneal cavity and plasma, Am. J. Physiol, 248(1 Pt 2), H15-H25, 1985.
114. Flessner, M. F., Osmotic barrier of the parietal peritoneum, Am. J. Physiol, 267(5 Pt 2), F861-F870, 1994.
115. Gotloib, L., Shustak, A., Bar-Sella, P., and Eiati, V., Heterogeneous density and ultrastructure of rabbit's peritoneal microvasculature, Int. J. Artif. Organs, 7(3), 123-125, 1984.
116. Suarbaker, P. H., Stuart, O. A., Vidal-Jove, J., Pessagno, A. M., and DeBruijn, E. A., Pharmacokinetics of the peritoneal-plasma barrier after systemic mitomycin x C administration, Cancer Treat. Res., 82, 41-52, 1996.
117. Walter, K. A., Tamargo, R. J., Olivi, A., Burger, P. C., and Brem, H., Intratumoral chemotherapy, Neurosurgery, 37(6), 1128-1145, 1995.
118. Mak, M., Fung, L., Strasser, J. F., and Saltzman, W. M., Distribution of drugs following controlled delivery to the brain interstitium, J. NeurooncoL., 26, 91-102, 1995.
119. Qin, D., Ma, J., Xiao, J., and Tang, Z., Effect of brain irradiation on blood-CSF barrier permeability of chemotherapeutic agents, Am. J. Clin. Oncol, 20(3), 263-265, 1997.
120. Freilich, R. J., Seidman, A. D., and DeAngelis, L. ML, Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel, Cancer, 76(2), 232-236, 1995.
121. Stewart, D. J., A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors, J. Neurooncol, 20(2), 121-139, 1994.
122. Heimans, J. J., Vermorken, J. B., Wolbers, J. G., Eeltink, C. M., Meijer, O. W., Taphoorn, M. J., and Beijnen, J. H., Paclitaxel (Taxol) concentrations in brain tumor tissue, Ann. Oncol., 5(10), 951-953, 1994.
123. Elliott, P. J., Hayward, N. J., Huff, M. R., Nagle, T. L., Black, K. L., and Battus, R. T., Unlocking the blood-brain barrier: a role for RMP-7 in brain tumor therapy, Exp. Neurol., 141(2), 214-224, 1996.
124. Burgess, P. K., Kulesa, P. M., Murray, J. D., and Alvord, E. C., Jr., The interaction of growth rates and diffusion coefficients in a three-dimensional mathematical model of gliomas, J. Neuropathol Exp. Neurol., 56(6), 704-713, 1997.
125. Zunkeler, B., Carson, R. E., Olson, J., Blasberg, R. G., DeVroom, H., Lutz, R. J., Saris, S. C., Wright, D. C., Kammerer, W., Patronas, N. J., Dedrick, R. L., Herscovitch, P., and Oldfield, E. H., Quantification and pharmacokinetics of blood-brain barrier disruption in humans, J. Neurosurg., 85(6), 1056-1065, 1996.
126. Sakamoto, A. and Ido T., Liposome targeting to rat brain: effect of osmotic opening of the blood-brain barrier, Brain Res., 629, 171-175, 1993.
127. Matsukado, K., Inamura, T., Nakano, S., Fukui, M., Bartus, R. T., and Black, K. L., Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7, Neurosurgery, 39(1), 125-133, 1996.
128. Koga, H., Inamura, T., Ikezaki, K., Nomura, T., Samoto, K., and Fukui, M., Increased delivery of a new cisplatin analogue (254-S) in a rat brain tumor by an intracarotid infusion of bradykinin, Neurol. Res., 18(3), 244-247, 1996.
129. Gennuso, R., Spigelman, M. K., Chinol, M., Zappulla, R. A., Nieves, J., Vallabhajosula, S., Alberto Paciucci, P., Goldsmith, S. J., and Holland, J. F., Effect of blood-brain barrier and blood-tumor barrier modification on central nervous system liposomal uptake, Cancer Invest., 11(2), 118-128, 1993.
130. Walker, W. L. and Cook, J., Drug delivery to brain tumors, Bull. Math. Biol, 1996; 58(6), 1047-1074, 1996.
131. El-Kareh, A. W. and Secomb, T. W., Effect of increasing vascular hydraulic conductivity on delivery of macromolecular drugs to tumor cells, Int. J. Radiat. Oncol. Biol Phys., 32(5), 1419-1423, 1995.
132. Nakano, S., Matsukado, K., and Black, K. L., Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide, Cancer Res., 56(17), 4027-4031, 1996.
133. Molnar, P., Lapin, G. D., and Groothuis, D. R., The effects of dexamethasone on experimental brain tumors. I. Transcapillary transport and blood flow in RG-2 rat gliomas, J. Neurooncol., 25(l), 19-28, 1995.
134. Tamargo, R, J., Myseros, J. S., Epstein, J. I., Yang, M. B., Chasin, M., and Brem, H., Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain, Cancer Res., 53(2), 329-333, 1993.
135. Reisfeld, B., Kalyanasundaram, S., and Leong, K., A mathematical model of polymeric controlled drug release and transport in the brain, J. Controlled Release, 36, 199207, 1995.
136. Saltzman, W. M. and Radomsky, M. L., Drugs released from polymers: diffusion and elimination in brain tissue, Chem. Eng. Sci., 46, 2429-2444, 1991.
137. Sipos, E. P., Tyler, B., Piantadosi, S., Burger, P. C., and Brem, H., Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain rumors, Cancer Chemother. Pharmacol, 39(5), 383-389, 1997.
138. Buahin, K. G. and Brem, H., Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release, J. Neurooncol., 26(2), 103-110, 1995.
139. Glantz, M. J., Hall, W. A., Cole, B. F., Chozick, B. S., Shannon, C. M., Wahlberg, L., Akerley, W., Marin, L., and Choy, H., Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status, Cancer, 75(12), 2919-2931, 1995.
140. Boulton, M., Flessner, M., Armstrong, D., Hay, J., and Johnston, M., Lymphatic drainage of the CNS: effects of lymphatic diversion/ligation on CSF protein transport to plasma, Am. J. Physiol, 272(5 Pt 2), R1613-R1619, 1997.
141. Morrison, P. F., Laske, D, W., Bobo, H., Oldfield, E. H., and Dedrick, R. L., Highflow microinfusion: tissue penetration and pharmacodynamics, Am. J. Physiol., 266(1 Pt 2), R292-R305, 1994.
142. Rosenberg, G., Kyner, W., and Estrada, E., Bulk flow of brain interstitial fluid under normal and hyperosmolar conditions, Am. J. Physiol., 238, F42-F49, 1980.
143. Kitamura, K., Takahashi, T., Miyagaki, T., Yamaoka, N., Tsurumi, H., Ohtsuji, E., Kamiguchi, M., Noguchi, A., and Yamaguchi, T., Efficacy and specificity of a monoclonal antibody-drug conjugate in chemotherapy by intratumoral injection, Jpn. J. Cancer Res., 83(7), 769-774, 1992.
144. Kitamura, K., Takahashi, T., Kotani, T., Miyagaki, T., Yamaoka, N., Tsurumi, H., Noguchi, A., and Yamaguchi T., Local administration of monoclonal antibody-drug conjugate: a new strategy to reduce the local recurrence of colorectal cancer, Cancer Res., 52(22), 6323-6328, 1992.
145. Kanellos, J., McKenzie, I. F., and Pietersz, G. A., Intratumor therapy of solid tumors with ricin-antibody conjugates, Immunol. Cell Biol., 67, 89-99, 1989.
146. Presant, C. A., Scolaro, M., Kennedy, P., Blayney, D. W., Flanagan, B., Lisak, J., and Presant, J., Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma, Lancet, 341(8855), 1242-1243, 1993.
147. Lasch, J., Laub, R., and Wohlrab, W., How deep do intact liposomes penetrate into human skin? J. Controlled Release, 18, 55-58, 1991.
148. Addicks, W. J., Weiner, N. D., Curl, R. L., and Flynn, G. L., Drug delivery from topical formulations: theoretical prediction and experimental assessment, in Topical Drug Delivery Formulations, Osborne, D. W, and Amann, A. H., Eds., Marcel Dekker, New York, 1990.
149. Khanna, C., Hasz, D. E., Klausner, J. S., and Anderson, P. M., Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies, Clin. Cancer Res., 2,721-734, 1996.
150. Juliano, R. L. and McCullough, H. N., Controlled delivery of an antitumor drug: localized action of liposome encapsulated cytosine arabinoside administered via the respiratory system, J. Pharmacol. Exp. Ther., 214(2), 381-387, 1980.
151. Yuan, F., Leunig, M., Huang, S. K., Berk, D. A., Papahadjopoulos, D., and Jain, R. K., Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft, Cancer Res., 54(13), 3352-3356, 1994.
152. Yuan, F., Dellian, M., Fukumura, D., Leunig, M., Berk, D. A., Torchilin, V. P., and Jain, R. K., Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size, Cancer Res., 55(17), 3752-3756, 1995.
153. Burrows, F. J., Overholser, J. P., and Thorpe, P. E., Potent antitumor effects of an antitumor endothelial cell immunotoxin in a murine vascular targeting model, Cell Biophys., 24-25, 15-25, 1994.
154. Burrows, F. J., Watanabe, Y., and Thorpe, P. E., A murine model for antibody-directed targeting of vascular endothelial cells in solid tumors, Cancer Res., 52(21), B954-B5962, 1992.
155. Hirano, K. and Hunt, C. A., Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration, J. Pharm. Sci., 74(9), 915-921, 1985.
156. Liu, J. and Li, M., The study of platinum concentration in retroperitoneal lymph nodes after intraperitoneal carboplatin in ovarian tumors (In Chinese), Chung-Hua Fu Chan Ko Tsa Chih, Chinese Journal of Obstetrics and Gynecology, 30(5), 273-275, 1995.
157. Alvarez, R. D., Partridge, E. E., Khazaeli, M. B., Plott, G., Austin, M., Kilgore, L., Russell, C. D., Liu, T., Grizzle, W. E., Schlom, J., LoBuglio, A. F., and Meredith, R. F., Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study, Gynecol. Oncol., 65(1), 94-101, 1997.
158. Hawley, A. E., Illum, L., and Davis, S. S., Preparation of biodegradable, surface engineered PLGA nanospheres with enhanced lymphatic drainage and lymph node uptake, Pharm. Res., 14(5), 657-661, 1997.
159. Cusack, B. J., Young, S. P., Driskell, J., and Olson, R. D., Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit, Cancer Chemother. Pharmacol, 32(1), 53-58, 1993.
160. de Valeriola, D., Dose optimization of anthracyclines, Anticancer Res., 14(6A), 2307-2313, 1994.
161. Burnett, M. B., Ransohoff, T. C., and Reardan, D., Mathematical modeling of tumor penetration of immunoconjugates, Antib. Immunoconj. Radiopharm., 4(2), 237(P-121), 1991.
162. Danckwerts, P. V., Unsteady-state diffusion or heat-conduction with moving boundary, Trans. Faraday Soc., 46, 701-712, 1950.
163. Burnette, R. R., Fundamental pharmacokinetic limits on the utility of using a sinusoidal drug delivery system to enhance therapy, J. Pharmacokinet. Biopharm., 20(5), 477-500, 1992.
164. Netti, P. A., Baxter, L. T., Boucher, Y., Skalak, R., and Jain, R. K., Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery, Cancer Res., 55(22), 5451-5458, 1995.
165. Secomb, T. W., Intaglietta, M., and Gross, J. F., Effects of vasomotion on microcirculatory mass transport: theoretical predictions, in Vasomotion and Flow Modulation in the Microcirculation, Intaglietta, M., Ed., Prog. Appl. Microcirc., 1989; 15:49-61.
166. Curti, B. D., Urba, W. J., Alvord, W. G., Janik, J. E., Smith, J. W., II, Madara, K., and Longo, D. L., Interstitial pressure of subcutaneous nodules in melanoma and lymphoma patients: changes during treatment, Cancer Res., 53(10 Suppl), 2204-2207, 1993.
167. Gridley, D. S., Slater, J. B., Mackensen, D. G., and Slater, J. M., Effect of preirradiation on radiopharmaceutical localization in human colon tumor xenografts using mono- and bispecific monoclonal antibodies, Anticancer Res., 16(6B), 3453-3458, 1996.
168. Sung, C., van Osdol, W. W., Saga, T., Neumann, R. D., Dedrick, R. L., and Weinstein, J. N., Streptavidin distribution in metastatic tumors pretargeted with a biotinylated monoclonal antibody: theoretical and experimental pharmacokinetics, Cancer Res., 54(8), 2166-2175,1994.
169. Martin, J., Stribbling, S. M., Poon, G. K., Begent, R. H., Napier, M., Sharma, S. K., and Springer, C. J., Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial, Cancer Chemother. Pharmacol., 40(3), 189-201, 1997.
170. Stribbling, S. M., Martin, J., Pedley, R, B., Boden, J. A., Sharma, S. K., and Springer, C. J., Biodistribution of an antibody-enzyme conjugate for antibody-directed enzytneprodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft, Cancer Chemother. Pharmacol., 40(4), 277-284, 1997.
171. van Osdol, W. W., Sung, C., Dedrick, R. L., and Weinstein, J. N., A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin, J. Nucl Med., 34(9), 1552-1564, 1993.
172. Sung, C. and van Osdol, W. W., Pharmacokinetic comparison of direct antibody targeting with pretargeting protocols based on streptavidin-biotin binding, J. Nucl Med., 36(5), 867- 876, 1995.
173. Gridley, D. S., Ewart, K. L., Cao, J. D., and Stickney, D. R., Hyperthermia enhances locafoation of In-III-labeled hapten to bifunctional antibody in human colon tumor xenografts, Cancer Res., 51, 1515-1520, 1991.
174. Cope, D. A., Dewhirst, M. W., Friedman, H. S., Signer, D. D., and Zalutsky, M. R., Enhanced delivery of a monoclonal antibody F(ab′)2 fragment to subcutaneous human glioma xenografts using local hyperthermia, Cancer Res., 50, 1803-1809, 1990.
175. Ausmus, P. L., Wilke, A. V., and Frazier, D. L., Effects of hyperthermia on blood flow and cis-diamminedichloroplatinum (II) pharmacokinetics in murine mammary adenocarcinomas nas, Cancer Res., 52(18), 4965-4968, 1992.
176. Hauck, M. L., Dewhirst, M. W., and Zalutsky, M. R., The effects of clinically relevant hyperthermic temperatures on the kinetic binding parameters of a monoclonal antibody, Nucl Med. Biol., 23(4), 551-557, 1996.
177. Takahashi, T., Mitsuhashi, N., Sakurai, H., and Niibe, H., Modifications of tumor-associated antigen expression on human lung cancer cells by hyperthermia and cytokine, Anticancer Res., 15(6B), 2601-2606, 1995.
178. Wilder, R. B., Langmuir, V. K., Mendonca, H. L., Goris, M. L., and Knox, S. J., Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts, Cancer Res., 53(13), 3022-3027, 1993.
179. Hauck, M. L., Coffin, D. O., Dodge, R. K., Dewhirst, M. W., Mitchell, J. B., and Zalutsky, M. R., A local hyperthermia treatment which enhances antibody uptake in a glioma xenograft model does not affect tumour interstitial fluid pressure, Int. J. Hyperthermia, 13(3), 307-316, 1997.
180. Dudar, T. E. and Jain, R. K., Differential response of normal and tumor microcirculation to hyperthermia, Cancer Res., 44(2), 605-612, 1984.
181. Schuster, J. M., Zalutsky, M. R., Noska, M. A., Dodge, R., Friedman, H. S., Bigner, D. D., and Dewhirst M. W., Hyperthermic modulation of radiolabeled antibody uptake in a human glioma xenograft and normal tissues, Int. J. Hyperthermia, 11(1), 59-72, 1995.
182. El-Kareh, A. W. and Secomb, T. W., Effect of extracellular volume fraction on tissue diffusivity and hydraulic conductivity, (in preparation).
183. Alien, T. M., Ahmad, I., Lopes de Menezes, D. E., and Moase, E. H., Immunoliposomemediated targeting of anti-cancer drugs in vivo, Biochem. Soc. Trans., 23(4), 1073-1079, 1995.
184. Alien, T. M., Mehra, T., Hansen, C., and Chin, Y. C., Stealth liposomes; an improved sustained release system for 1-beta-D-arabinofuranosylcytosine, Cancer Res., 52(9), 2431-2439, 1992.
185. Litzinger, D. C., Buiting, A. M., van Rooijen, N., and Huang, L., Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)containing liposomes, Biochim. Biophys. Acta, 1190(1), 99-107, 1994.
186. Liu, D., Mori, A., and Huang, L., Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM1-containing liposomes, Biochim. Biophys. Acta, 1104(1), 95-101, 1992.
187. Oku, N., Tokudome, Y., Tsukada, H., and Okada S., Real-time analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography, Biochim. Biophys. Acta, 1238, 86-90, 1995.
188. Allen, T. M., Hansen, C. B., and Guo, L. S., Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection, Biochim. Biophys. Acta, 1150(1), 9-16, 1993.
189. Zou, Y., Ling, Y. H., Reddy, S., Priebe, W., and Perez-Soler, R., Effect of vesicle size and lipid composition on the in vivo tumor selectivity and toxicity of the noncrossresistant anthracycline annamycin incorporated in liposomes, Int. J. Cancer, 61(5), 666-671, 1995.
190. Wu, N. Z., Da, D., Rudoll, T. L., Needham, D., Whorton, A. R., and Dewhirst, M. W., Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue, Cancer Res., 53(16), 3765-3770, 1993.
191. Huang, S. K., Lee, K. D., Hong, K., Friend, D. S., and Papahadjopoulos, D., Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice, Cancer Res., 52(19), 5135-5143, 1992.
192. Emanuel, N., Kedar, E., Bolotin, E. M., Smorodinsky, N. I., and Barenholz, Y., Targeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing mice, Pharm. Res., 13(6), 861-868, 1996.
193. Lübbe, A. S., Bergemann, C., Huhnt, W., Fricke, T., Riess, H., Brock, J. W., and Huhn, D., Preclinical experiences with magnetic drug targeting; tolerance and efficacy, Cancer Res., 56(20), 4694-4701, 1996.
194. Lübbe, A. S., Bergemann, C., Riess, H., Schriever, F., Reich ardt, P., Possinger, K., Matthias, M., Dorken, B., Herrmann, F., Gurtler, R., Hohenberger, P., Haas, N., Sohr, R., Sander, B., Lemke, A. J., Ohlendorf, D., Huhnt, W., and Huhn, D., Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors, Cancer Res., 56(20), 4686-4693, 1996.
195. Viroonchatapan, E., Sato, H., Ueno, M., Adachi, I., Tazawa, K., and Horikoshi, I., Magnetic targeting of thermosensitive magnetoliposomes to mouse livers in an in situ on-line perfusion system, Life Sci., 58(24), 2251-2261, 1996.
196. Masuko, Y., Tazawa, K., Viroonchatapan, E., Takemori, S., Shimizu, T., Fujimaki, M., Nagae, H., Sato, H., and Horikoshi, I., Possibility of thermosensitive magnetoliposomes as a new agent for electromagnetic induced hyperthermia, Biol. Pharm. Bull., 18(12), 1802- 1804, 1995.
197. Shinkai, M., Yanase, M., Honda, H., Wakabayashi, T., Yoshida, J., and Kobayashi, T., Intracellular hyperthermia for cancer using magnetite cationic liposomes: in vitro study, Jpn. J. Cancer Res., 87(11), 1179-1183, 1996.
198. Gallo, J. M., Hung, C. T., Gupta, P. K., and Perrier, D. G., Physiological pharmacokinetic model of adriamycin delivered via magnetic albumin microspheres in the rat, J. Pharmacokinet. Biopharm., 17(3), 305-326, 1989.
199. Jain, R. K., Transport of molecules in the tumor interstitium: a review, Cancer Res., 47, 3039-3051, 1987.
200. Jain, R. K., Transport of molecules across tumor vasculature, Cancer Metastasis Rev., 6, 559-594, 1987.
201. Gerlowski, L. E. and Jain, R. K., Microvascular permeability of normal and neoplastic tissues, Microvasc. Res., 31(3), 288-305, 1986.
202. Yuan, F., Leimig, M., Berk, D. A., and Jain, R. K., Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice, Microvasc. Res., 45(3), 269-289, 1993.
203. Yuan, F., Salehi, H. A., Boucher, Y., Vasthare, U. S., Tuma, R. F., and Jain, R. K., Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows, Cancer Res., 54(17), 4564-4568, 1994.
204. Yee, C. and Shiu, R. P. C., Degradation of endothelial basement membrane by human breast cancer cell lines, Cancer Res., 46, 1835-1839, 1986.
205. Chary, S. R. and Jain, R. K., Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluoresence photobleaching, Proc. Natl. Acad. Sci. U.S.A., 86, 5385-5389, 1989.
206. Clauss, M. A. and Jain, R. K., Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues, Cancer Res., 50, 3487-3492, 1990.
207. Adany, R., Ed., Tumor Matrix Biology, CRC Press, Boca Raton, 1995.
208. El-Karen, A. W., Braunstein, S. L., and Secomb, T. W., Effect of cell arrangement and interstitial volume fraction on the diffusivity of monoclonal antibodies in tissue, Biophys. J., 64(5), 1638-1646, 1993.
209. Clague, D. S. and Phillips, R. J., Hindered diffusion of spherical macromolecules through dilute fibrous media, Phys. Fluids, 8(7), 1720-1731, 1996.
210. Clague, D. S. and Phillips, R. J., A numerical calculation of the hydraulic permeability of three-dimensional disordered fibrous media, Phys. Fluids, 9(6), 1562-1572, 1997.
211. O'Donoghue, J. A., Bardies, M., and Wheldon, T. E., Relationships between tumor size and curability for uniformly targeted therapy with beta-emitting radionuclides, J. Nuclear Med., 36(10), 1902-1909, 1995.
212. Flux, G. D., Webb, S., Ott, R. J., Chittenden, S. J., and Thomas, R., Three-dimensional dosimetry for intralesional radionuclide therapy using mathematical modeling and multimodality imaging, J. Nucl. Med., 38(7), 1059-1066, 1997.
213. Weber, W., Weber, J., and Senekowitsch-Schmidtke, R., Therapeutic effect of m-[131I]and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes, Cancer Res., 56(23), 5428-5434, 1996.
214. Secomb, T. W., Hsu, R., Dewhirst, M. W., Klitzman, B., and Gross, J. F., Analysis of oxygen transport to tumor tissue by micro vascular networks, Int. J. Radiat. Oncol. Biol. Phys., 25, 481-489, 1993.
215. Himmelstein, K. J. and Bischoff, K. B., Mathematical representations of cancer chemotherapy effects, J. Pharmacokinet. Biopharm., 1(1), 51-68, 1973.
216. Bischoff, K. B., Dedrick, R. L., Zaharko, D. S., and Longstreth, J. A., Methotrexate pharmacokinetics, J. Pharm. Sci., 60(8), 1128-1133, 1971.
217. Steel, G. G., Growth kinetics of tumors: cell population kinetics in relation to the growth and treatment of cancer, Clarendon Press, Oxford, 1977.
218. Dedrick, R., Bischoff, K. B., and Zaharko, D. S., Interspecies correlation of plasma concentration history of methotrexate (NSC-740), Cancer Chemother. Rep. - Part 1, 54(2), 95-101, 1970.
219. Dedrick, R. L., Animal scale-up, J. Pharm. Biopharmacol., 1, 435-461, 1973.
220. Dedrick, R. L. and Bischoff, K. B., Species similarities in pharmacokinetics, Federation Proc., 39(1), 54-59, 1980.
221. Dedrick, R. L., Interspecies scaling of regional drug delivery, J. Pharm. Sci., 75(11), 1047-1052, 1986.
222. West, G. B., Brown, J. H., and Enquist, B. J., A general model for the origin of allometric scaling laws in biology, Science, 276, 122-126, 1997.
223. Paxton, J. W., The allometric approach for interspecies scaling of pharmacokinetics and toxicity of anti-cancer drugs, Clin. Exp. Pharmacol. Physiol., 22(11), 851-854, 1995.
224. Terasaki, T., Iga, T., Sugiyama, Y., and Hanano, M., Pharmacokinetic study on the mechanism of tissue distribution of doxorubicin: interorgan and interspecies variation of tissue-to-plasma partition coefficients in rats, rabbits, and guinea pigs, J. Pharm. Sci., 73(10), 1359-1363, 1984.
225. Antoniw, P., Farnsworth, A. P., Turner, A., Haines, A. M., Mountain, A., Mackintosh, J., Shochat, D., Humm, J., Welt, S., Old, L. J., Yarranton, G, T., and King, D. J., Radioimmunotherapy of colorectal carcinoma xenografts in nude mice with yttrium-90 A33 IgG and Tri-Fab (TFM), Br. J. Cancer, 74(4), 513-524, 1996.
226. Kubota, T., Inoue, S., Furukawa, T., Ishibiki, K., Kitajima, M., Kawamura E., and Hoffman, R. M., Similarity of serum-tumor pharmacokinetics of antitumor agents in man and nude mice, Anticancer Res., 13(5A), 1481-1481, 1993.
227. Inaba, M., Kobavashi, T., Tashiro, T., and Sakurai, Y., Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice, Jpn. J. Cancer Res., 79(4), 509-516, 1988.
228. Finn, C. and Sadee, W., Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography, Cancer Chemother. Rep. - Part 1, 59(2 pt 1), 279-286, 1975.
229. Russo, R., Bartosek, I., Piazza, E., Santi, A. M., Libretti, A., and Garattini, S., Differential pulse polarographic determination of BCNU pharmacokinetics in patients with lung cancer, Cancer Treat. Rep., 65(7-8), 555-562, 1981.
230. DeConti, R. C., Toftness, B. R., Lange, R. C., and Creasey, W. A., Clinical and pharmacological studies with cis-diamminedichloroplatinum (II), Cancer Res., 33(6), 1310-1315, 1973.
231. Dennis, M. J., Beijuen, J. H., Grochow, L. B., and van Warmerdam, L. J., An overview of the clinical pharmacology of topotecan, Semin. Oncol., 24(1 Suppl 5), S5-12-S5-18, 1997.
232. Elferink, F., van der Vijgh, W. J., Klein, L, Vermerken, J. B., Gall, H. E., and Pinedo, H. M., Pharmacokinetics of carboplatin after i.v. administration, Cancer Treat. Rep., 71(12), 1231-1237, 1987.
233. Robert, J., Illiadis, A., Hoerni, B., Cano, J. P., Durand, M., and Lagarde, C., Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response, Eur. J. Cancer Clin. Oncol., 18(8), 739-745, 1982.
234. Ehninger, G., Proksch, B., Schmidt, H., Waidelich, P., Eichel, B., and Dopfer, R., Unaltered pharmacokinetics after the administration of high-dose etoposide without prior dilution, Cancer Chemother. Pharmacol., 28(3), 214-216, 1991.
235. Hande, K. R., Wedlund, P. J., Noone, R. M., Wilkinson, G. R., Greco, F. A., and Wolff, S. N., Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Res., 44(1), 379-382, 1984.
236. Creaven, P., Raghavan, D., Pendyala, L., Perez, R., Loewen, G., Meropol, N., Levine, E., and Hicks, W., Phase I study of paclitaxel and carboplatin: implications for trials in head and neck cancer, Semi. Oncol., 22(5 Suppl 12), 13-16, 1995.
237. Horikoshi, N., Inoue, K., Aiba, K., Mukaiyama, T., Ogihara, A., Sumida, T., Akatsuka, Y., Besho, A., Inamoto, Y., Uchida T., et al., Phase I study of paclitaxel (In Japanese), Gan to Kagaku Ryoho, Japanese Journal of Cancer and Chemotherapy, 21(14), 2407-2414, 1994.
238. Piscitelli, S. C., Wells, M. J., Metcalf, J. A., Baseler, M., Stevens, R., and Davey, R. T., Jr., Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients, Pharmacotherapy, 16(5), 754-759, 1996.
239. Lotze, M. T., Frana, L. W., Sharrow, S. O., Robb, R. J., and Rosenberg, S. A., In vivo administration of purified human interleukin 2. I. Half-life and immunologie effects of the Jurkat cell line-derived interleukin 2, J. Immunol., 134(1), 157-166, 1985.
240. Pais, R. C., Ingrim, N. B., Garcia, M. L., Abdel-Mageed, A., McKolanis, J., Ingrim, M. E., Hnath, R. S., Ziegler, K., and Ragab, A. H., Pharmacokinetics of recombinant interleukin2 in children with malignancies pediatric oncology group study, J. Biol. Response Modifiers, 9(5), 517-521, 1990.
241. Molthoff, C. F., Pinedo, H. M., Schluper, H. M., Nijman, H. W., and Boven, E., Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab′)2 fragments in experimental ovarian cancer, Br. J. Cancer, 65(5), 677-683, 1992.
242. Goldenberg, D. M., Horowitz, J. A., Sharkey, R. M., Hall, T. C., Murthy, S., Goldenberg, H., Lee, R. E., Stein, R., Siegel, J. A., Izon, D. O., et al., Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody, J. Clin. Oncol., 9(4), 548-564, 1991.
243. Gabizon, A., Isacson, R., Libson, E., Kaufman, B., Uziely, B., Catane, R., Ben-Dor, C. G., Rabello, E., Cass, Y., Peretz, T., et al., Clinical studies of liposome-encapsulated doxorubicin, Acta Oncol., 33(7), 779-786, 1994.
244. Van Belle, S. J., De Smet, M. C., De Mey, J. E., and Storme, G. A., Cellular pharmacokinetics of vinblastine and other vinca alkaloids in MO4 cells, Anticancer Res., 11(1), 465-471, 1991.
245. Nelson, R. L., Dyke, R. W., and Root, M. A., Clinical pharmacokinetics of vindesine, Cancer Chemother. Pharmacol., 2(4), 243-246, 1979.
246. Nelson, R. L., The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer, Med. Pediatr. Oncol, 10(2), 115-127, 1982.
247. Lazo, J. S., Schisselbauer, J. C., Meandzija, B., and Kennedy, K. A., Initial single-strand DNA damage and cellular pharmacokinetics of bleomycin A2, Biochem. Pharmacol., 38(13), 2207-2213, 1989.
248. Takemura, Y., Kobayashi, H., Miyachi, H., Hayashi, K., Sekiguchi, S., and Ohnuma, T., The influence of tumor cell density on cellular accumulation of doxorubicin or cisplatin in vitro, Cancer Chemother. Pharmacol., 27(6), 417-422, 1991.
249. Durand, R. E. and Olive, P. L., Flow cytometry studies of intracellular adriarnycin in single cells in vitro, Cancer Res., 41(9 Pt 1), 3489-3494, 1981.
250. Krishan, A. and Ganapathi R., Laser flow cytometric studies on the intracellular fluorescence of anthracyclines, Cancer Res., 40(11), 3895-3900, 1980.